Quetiapine Fumarate Tablet
Product Images NDC 87441-073

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Quetiapine Fumarate (NDC 87441-073). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Quetiapine 200 mg (8744107301 Quetiapine 200 mg)

Quetiapine 200 mg (8744107301 Quetiapine 200 mg)
Label for Quetiapine Tablets USP 200 mg. Film-coated tablets containing 230.24 mg quetiapine fumarate USP equivalent to 200 mg quetiapine. Repackaged by Unit Dose Solutions, Inc., Raleigh, NC and distributed by Tuckhoe Enterprises, LLC, Henrico, VA. Includes storage instructions and pharmacist dispensing note.*
FDA Label Image

Molecular Structure (874e50ad 5da0 4ac3 9290 79442c91399e 01)

Molecular Structure (874e50ad 5da0 4ac3 9290 79442c91399e 01)
Chemical structure of quetiapine fumarate, the active ingredient shown in the image, consisting of the quetiapine molecule and fumarate ions.*
FDA Label Image

Figure 1 (874e50ad 5da0 4ac3 9290 79442c91399e 02)

Figure 1 (874e50ad 5da0 4ac3 9290 79442c91399e 02)
A line graph showing the proportion of patients with relapse (%) over time (weeks) comparing two treatment groups: QTP+LI/VAL (quetiapine with lithium/valproate) and PLA+LI/VAL (placebo with lithium/valproate). The graph illustrates relapse rates increasing over 100 weeks, with the placebo group showing a higher relapse proportion than the quetiapine group.*
FDA Label Image

Figure 2 (874e50ad 5da0 4ac3 9290 79442c91399e 03)

Figure 2 (874e50ad 5da0 4ac3 9290 79442c91399e 03)
A Kaplan-Meier survival curve graph showing the proportion of patients with relapse over time (weeks) comparing two groups: QTP+LI/VAL (dashed line) and PLA+LI/VAL (solid line). The Y-axis represents the proportion of patients with relapse (%) ranging from 0 to 100, and the X-axis shows time in weeks from 0 to 100.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.